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Abstract
Background: T-cell receptor diversity correlates with immune competency and is of particular interest in patients
undergoing immune reconstitution. Spectratyping generates data about T-cell receptor CDR3 length distribution for
each BV gene but is technically complex. Flow cytometry can also be used to generate data about T-cell receptor BV
gene usage, but its utility has not been compared to or tested in combination with spectratyping.
Results: Using flow cytometry and spectratype data, we have defined a divergence metric that quantifies the
deviation from normal of T-cell receptor repertoire. We have shown that the sample size is a sensitive parameter in the
predicted flow divergence values, but not in the spectratype divergence values. We have derived two ways to correct
for the measurement bias using mathematical and statistical approaches and have predicted a lower bound in the
number of lymphocytes needed when using the divergence as a substitute for diversity.
Conclusions: Using both flow cytometry and spectratyping of T-cells, we have defined the divergence measure as
an indirect measure of T-cell receptor diversity. We have shown the dependence of the divergence measure on the
sample size before it can be used to make predictions regarding the diversity of the T-cell receptor repertoire.
Background
The immune system’s ability to fight a large array of for-
eign particles is facilitated by the diversity of the T-cell
receptor (TCR) repertoire [1]. This diversity is generated
during thymocyte development by a process of somatic
recombination. Inside the thymus, the constant (C) and
variable (V) domains of the α and β chains of the TCR
are assembled via random genetic rearrangements of the
variable (V), diversity (D) and joining (J) gene segments
[2]. Additional diversity is added through imprecise join-
ing of the V and J regions along with random nucleotide
additions and deletions at the V(D)J junctions [2,3]. Con-
sequently, most of the variability lies in the third com-
plementary determining region (CDR3) which is encoded
by the V(D)J junction and comes in contact with the
antigenic peptide on the surface of peptide/major his-
tocompatibility complex (pMHC) molecules [4,5]. While
the total number of lymphocytes in the blood can be
directly measured, assessment of the diversity of the TCR
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repertoire requires more complex and indirect assays in
a research setting. Such assays include flow cytometry,
spectratyping and nucleotide sequencing.
Different T-cell clones use different V gene families in
the rearrangement of their β chains. Through the use
of commercially available monoclonal antibodies (named
TCR Vβ), one can use standard flow cytometry on whole
blood samples to determine the percentage of CD4 T-cells
that use a given TCR BV family in subjects or controls.
Measures of heterogeneity of TCR BV family usage in
these CD4 T-cells can be used as a substitute for TCR
repertoire diversity [6]. Flow cytometry is not only faster,
cheaper, and technically simpler to use; the data reflects
real population percentages.
Spectratyping uses messenger RNA (mRNA) from
T-cells to amplify, by PCR, the complementary DNA
(cDNA) across the CDR3 region. This generates informa-
tion about the heterogeneity of the relative frequencies of
different CDR3 length products within a functional TCR
BV family. Because different T-cell clones have different
sequences or lengths of CDR3, analysis of the CDR3
length distributions can be used to determine the over-
all TCR repertoire diversity [7-11]. Spectratyping has the
advantage of providing a finer level of resolution than
© 2013 Ciupe et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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just analyzing BV gene family expression on the T-cells of
flow cytometry. Although spectratyping provides the total
number of CDR3 sizes and their pattern of distribution,
the investigator cannot determine the frequency of cells
used by a particular BV family. Amplifications of varia-
tions from a background distribution of each individual
BV family may lead to over-representation of immun-
odominant clonotypes and therefore yield results that are
not representative of the contribution of those cells in the
entire T-cell repertoire.
TCR diversity can also be assessed by nucleotide
sequencing of DNA CDR3 regions, but this is labor-
intensive and generates an even lower level of resolution
of the whole T-cell repertoire compared to spectratyping
[12].
This paper focuses on the role of flow cytometry in
measuring T-cell population diversity and compares it to
T-cell population diversity as given by spectratyping. Tra-
ditionally, spectratyping data is quantified using a wide
range of methods from visual [13,14] to quantitative scor-
ing [15-17]. Our group previously described the use of a
likelihood method for measuring deviation from a normal
TCR repertoire [9,11]. For each observed CDR3 length
distribution by spectratyping, we compute the Kullback-
Leibler divergences between the patient CDR3 length dis-
tribution and a known reference distribution [9,11]. We
havemodified the Kullback-Leibler divergence tomeasure
the deviation of T-cell receptor diversity from normal.
This was done by accounting for both the TCR BV family
usage as measured by flow cytometry and by comparing
the utility of this method to CDR3 length distribution as
measured by spectratyping [11].
Estimator bias is a concern when using this method of
divergence scoring. In particular, it is desirable to deter-
mine howmuch deviation in the computation of the diver-
gence occurs when the initial number of lymphocytes
used in generating the data is varied. We have addressed
this question in the context of divergence measures gen-
erated individually by flow cytometry and spectratyping.
The results are especially useful when using the tech-
niques for limited numbers of cells.
Results
We used the Kullback-Leibler divergence to quantify sim-
ilarities between different frequency distributions in the
T-cell repertoire diversity when measured by either flow
cytometry or spectratyping. We started with two assump-
tions: 1) the reference distribution corresponds to a poly-
clonal TCR repertoire and 2) in individual subjects, a
positive divergence determines the deviation from the
normal TCR repertoire. The flow divergence, Df , is the
distance between the individual and the perfectly sam-
pled reference control distributions of all TCR BV fam-
ily usage measured by flow cytometry. The spectratype
divergence, Ds, is the distance between the individual and
the perfectly sampled reference control distributions of
the CDR3 lengths of each TCR BV family and averaged
over all TCR BV families as measured by spectratyping
(see section Kullback-Leibler divergence and [9]).
We specifically wanted to assess the performance of the
divergences Df and Ds in predicting the diversity of the
T-cell receptor repertoire under stressful, i.e. cell limited,
circumstances. While Df and Ds account for deviations
from normal of distributions of TCR BV family usage and
CDR3 lengths within each TCR BV family, additional vari-
ability is added due to the dependence on the number of
measured events, n, for every individual patient/control
(see Figures 1 and 2). Knowing the sample size n and
the dimensions of the measured space, Li, we derived the
corrected divergence value, Di,corr (see section ‘Sampling
bias - theoretical derivation’) to be given by
Di,corr = Di − Li − 12n , (1)
where i = f , s for flow cytometry and spectratyping,
respectively. Lf is the number of BV families used in the
flow cytometry assay (in our case 18) and Ls is the num-
ber of CDR3 lengths used in the spectratype assay (in our
case 14).
Therefore, only the number of measured events, n, and
the dimension of the measured space, Li are needed to
correct the divergence measures. We used this formula
to assess the performance of Df and Ds measures in
an athymic DiGeorge subject (Figure 1) during a period
of limited numbers of peripheral blood T-cells as the
patient underwent immune reconstitution following thy-
mus transplantation.
Flow cytometry results
Flow divergence measurements, Df , were determined at
seven time points following thymus transplantation in
DiGeorge subject 5 (Table 1). For each time point, the
number of CD4 T-cell was known (Table 1). The corrected
divergence Df ,corr is found by subtracting (Lf − 1)/2n,
where Lf = 18, from the measured divergence Df at each
time point (Table 1). The measured and corrected diver-
gences as a function of 1/n are plotted in Figure 1(a).
When we use samples with low event numbers, we noted
an overestimate in the measured Df compared to Df
estimates from samples with high event numbers, for
which the correction is not significant. Formula (1) helped
address the effect of event number on the Df prediction.
To further test the dependence of Df on the sample size
we assumed that Df is a function of the decreasing event
numbers in the CD4 T-cell gate used for TCR BV analysis.
For this analysis we used a single blood sample collec-
tion from each of four complete DiGeorge subjects after
thymus transplantation and from each of four healthy
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Figure 1Measured and corrected divergence measures as function of inverted sample number. (a)Measured flow divergence, Df , (red solid
diamonds) and corrected flow divergence, Df ,corr , (blue circles) as functions of the inverted sample number 1/n; (b)Measured spectratype
divergence, Ds , (red empty diamonds) and corrected spectratype divergence, Ds,corr, (blue circles) as a function of the inverted sample number 1/n0
in one DiGeorge patient.
controls. Each blood sample was serially diluted, followed
by flow cytometry. The results are presented in Table 2
and the plot of Df as a function of n is presented in
Figure 2.
For each of these eight cases, we wanted to predict the
corrected divergence value, Df ,corr, using the measured
Df s and determine their dependence on the sample size n.
We define a three parameter linear model given by
y(n) = α + C/n + ε, (2)
where, y(n) is the observed Df and n is the number of
CD4 T-cells in the sample. The intercept α is the true
divergence, Df ,corr, and the slope C quantifies the rate
at which the diversity is dependent on the sample size.
In equation (1), slope C corresponds to the (Lf − 1)/2
value, which for an assay that uses 18 BV families, reduces
to 8.5. The errors, ε, are independent and normally
distributed.
We derived estimates and 95% confidence intervals for
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Figure 2 Flow divergence,Df , as a function of sample size n (•), presented on a log-log scale.
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Table 1 Average CD4 T-cell sample size, measured flow
divergenceDf , and corrected flow divergenceDf , corr in a
DiGeorge subject
Days after Average CD4 nr Measured flow Corrected flow
transplant in gate (n) Df value Df , corr value
70 341 0.47 0.44
88 103 1.02 0.94
117 174 0.39 0.34
145 581 0.129 0.11
181 737 0.103 0.091
398 1569 0.063 0.057
868 4514 0.06 0.058
Values are measured over time following thymic transplantation.
y(n), as given by (2), to the measured Df values in Table 1
for CD4 T-cell numbers n. For the fitting routine we used a
descent method for univariate functions [18]. The param-
eter values and their confidence intervals are presented in
Table 3. The regression curves and data are presented in
Figure 3.
Moreover, if we consider the slope C to be equal among
the subjects we can simultaneously fit the followingmodel
to the data from all subjects.
yi(n) = αi + C/n + εi, (3)
where αi are the corrected divergence values for the
patient i, with i = 1, ..., 8. The rate at which the diversity
is dependent on the sample size, C, is considered constant
among the subjects. The errors for each of the subjects, εi,
are independent and normally distributed.
The fitting procedure was done using a quasi-Newton
method for finding the minimum of a multivariate func-
tion [18]. The predicted parameter values and their con-
fidence intervals are presented in Table 4. The regression
curves and data are presented in Figure 4.
Events estimation
From the flow cytometry analysis we can estimate the
minimum number of CD4 T-cells needed in a sample for
an accurate Df ,corr estimate. If we want our estimates to
be 90% accurate, i.e., err = 0.1, then the ratio between
the corrected and measured divergence has to be less
than err,
1/nC
α + 1/nC < err. (4)
This translates into the following condition
n > C(1 − err)err × α . (5)
Table 2 Summary of T-cell sample size and the
corresponding flow divergence valuesDf
Subject Average CD4 T-cell nr Measured flow
in gate n divergenceDf



































From our estimates C = 7.705 and α = 0.19 (median
0.12). This implies the sample size, n, must be larger than
364 (median 577) cells for an accurate Df ,corr estimate. In
our case, we gated the flow cytometry on CD4 T-cells, so
more than 364 CD4 T-cells, or events, must be captured
in the flow analysis.
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Table 3 Parameter values and confidence intervals for
model (2)
Subject Value CI
Control 1 α 0.107 [0.079,0.135]
C 9.7 [6.1, 13.4]
Control 2 α 0.07 [0.02,0.129]
C 10.9 [4.7, 17.2]
Control 3 α 0.111 [-0.17,0.373]
C 6.9 [-29, 43]
Control 4 α 0.02 [-0.027,0.067]
C 13 [2, 24]
Subject 1 α 0.39 [0.214, 0.574]
C 25 [-6.3, 56]
Subject 2 α 0.32 [0.253, 0.377]
C 21.3 [14.5, 28.1]
Subject 3 α 0.205 [0.087, 0.322]
C 5.5 [0.7, 10.4]
Subject 4 α 0.113 [-0.116, 0.342]
C 7.9 [-33, 49]
Spectratype results
Spectratype divergence measurements, Ds, were deter-
mined in five patients for three to seven time points
following thymic transplantation (Table 5). For each time
point, the number of CD3 T-cell used to isolate RNA, n0,
is known (Table 5). Starting with a fixed amount of RNA,
complementary DNA (cDNA) is generated in a reverse
transcriptase reaction and used with each of π = 23 dif-
ferent primers to amplify the CDR3 region from each BV
gene.
The correctedDs,corr is found by subtracting (Ls−1)/2n,
where n = n0/π , from the measured divergence at each
time point, where Ls = 14 (Table 5). The measured and
corrected divergences as a function of 1/n0 are plotted
in Figure 1(b). We note that there is no correction in the
measured spectratype divergence,Ds, since the number n0
of CD3 T-cells that we are starting with is always high.
Total divergence
By combining the individual contributions of flow and
spectratype divergence, we defined the total divergence,
D (see section ‘Kullback-Leibler divergence’). D measures
the divergence of the individual from the perfectly sam-
pled reference control and accounts for differences in
distributions of CDR3 lengths within each TCR BV fam-
ily by spectratyping as well as differences in distributions
of overall TCR BV families by flow cytometry. Correc-
tions in the flow and spectratype divergences are sufficient
to ensure that the total divergence is independent of the
sample size.
Discussion
The data used in our study came from flow cytometry and
spectratype assays in both DiGeorge subjects after thymus
transplantation and healthy adult volunteers. This study
























































Control 4Control 3Control 2
Subject 3Subject 2Subject 1
Figure 3 Flow divergenceDf as a function of the inverted sample number 1/n in eight subjects. The solid line represents the fit of the three
parameter linear model (2) to the data (•). Results are presented on a log-log scale. The same model was fitted to a data set that excluded point
(0.0017, 0.366) for control 3 (dashed line). The best parameter estimates and their 90% confidence intervals are presented in Table 3.
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Table 4 Parameter values and confidence intervals for
model (3)
Subject α CI
Control 1 0.117 [0.033,0.202]
Control 2 0.085 [0.009,0.161]
Control 3 0.107 [0.032,0.184]
Control 4 0.039 [-0.045,0.123]
Subject 1 0.46 [0.38, 0.55]
Subject 2 0.41 [0.32, 0.49]
Subject 3 0.175 [0.089, 0.261]
Subject 4 0.113 [0.029, 0.2]
Subject C CI
All 7.705 [4.55, 10.85]
flow cytometry, as well as spectratyping, to assess the
diversity of the antigen receptor repertoire. Importantly,
these data identify a bias in measurement errors which
must be corrected. The paper presents the relationships
between the number of gated events in the flow cytom-
etry assay, as well as the number of CD3 T-cells in the
spectratype assay, and the information-theory measures,
Df and Ds, used as surrogates of TCR diversity.
We addressed a critical issue of estimator bias. Start-
ing with the assumption that such a bias exists, we have
derived ways to account for the error in the measured
divergences. We show that Df and Ds can be corrected
by substracting a number inversely proportional to the
sample size.
For the flow cytometry data, the constant of propor-
tionality can either be deduced theoretically as a function
of the total number of BV TCR families used in the
flow cytometry assay, or derived from a statistical model
applied to individual data. Both methods predict similar
results, with the constant equal to 8.5 in the theoretical
approach and 7.7 in the statistical approach. It is impor-
tant to note that we found a direct correlation between
the measured Df and the sample size in five out of eight
subjects (see Table 6).
Our study allows us to predict a lower bound for the
number of CD4 T-cells needed in the flow cytometry
gated events. We have shown that at least 364 CD4 T-
cells have to be counted as gated events for a 90% con-
fidence in the Df measures. With fewer gated events,
the Df measurement cannot be used as a substitute for
diversity. This is particularly important to keep in mind
when assessing patients with limited numbers of T-cells,
such as those undergoing immune reconstitution follow-
ing thymus, stem cell or bone marrow transplantation.
Each of these is a clinical situation in which the devel-
opment of the T-cell repertoire correlates to immune
competency. Thus, these data provide a quantitative basis
by which T-cell repertoire diversity can be assessed by
flow cytometry.
For the spectratype data, the results are quite different.
Although, using the same theoretical approach, we derive


















Figure 4 Flow divergenceDf as a function of the inverted sample number 1/n for the same slopeC. The solid and dashed lines shows the fit
of a three parameter linear model (3) to the data (•). The results are presented on a log-log scale. The best parameter estimates and their 90%
confidence intervals are presented in Table 4.
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Table 5 CD3 T-cell sample size, measured spectratype divergenceDs, and corrected spectratype divergenceDs,,corr in a
DiGeorge subject
Subject Days after transplant CD3 T-cells n0 MeasuredDs value CorrectedDs, corr value
Subject 1 9 420,000 0.91 0.9096
34 12,220,000 0.61 0.61
70 550,000 0.97 0.9697
Subject 4 540 670,000 0.039 0.0388
1540 1,260,000 0.073 0.0729
2017 1,140,000 0.076 0.0759
Subject 5 70 700,000 1.15 1.1498
88 400,000 0.83 0.8296
117 700,000 0.41 0.4098
145 1,000,000 0.46 0.4599
181 1,080,000 0.106 0.1059
398 2,000,000 0.116 0.1159
Subject 6 175 1,440,000 0.107 0.1069
209 800,000 0.168 0.1678
286 1,480,000 0.086 0.0859
730 1,200,000 0.12 0.1199
Subject 7 102 380,000 0.43 0.4296
130 460,000 0.23 0.2297
166 500,000 0.08 0.0797
372 1,250,000 0.14 0.1399
Values are measured over time following thymic transplantation.
thus, the corrected spectratype divergence is identical
to the observed divergence. Moreover, we find no cor-
relation between the measured spectratype divergence,
Ds, and the sample size in four out of five patients
(Table 7).
The total divergence actively incorporates the flow
divergence. Correction in the flow divergence, Df , guar-
antees independence of the total divergence, D, from the
sample size.
Conclusions
In conclusion, sample size is a sensitive parameter in the
predicted flow divergence values, but not in the spec-
tratype divergence values. Although using flow cytom-
etry to assess T-cell repertoire diversity is a valuable
tool, one must have sufficient cells, or events, in the
flow cytometry gate before using either the flow or the




Blood samples used in our study come from healthy
adult controls and from infants with complete DiGeorge
anomaly after thymus transplantation [19]. Blood was
obtained under protocols approved by Duke University
Medical Center Internal Review Board (IRB). T-cell reper-
toire evaluation was done by flow cytometry. Whole
blood samples were evaluated using 22 monoclonal anti-
bodies directed against CD4 and a total of 18 TCR BV
families (Beckman Coulter and BD Biosciences - see
Tables 8 and 9).
Table 6 Correlation coefficient and p-values as given by a
Pearson comparison test, between the inverse average
number of CD4 T-cell used in flow cytometry assays and
the flow divergence
Subject Correlation coefficient p-value
Control 1 0.99 0.0076
Control 2 0.98 0.0031
Control 3 0.32 0.58
Control 4 0.96 0.035
Subject 1 0.92 0.075
Subject 2 0.99 0.005
Subject 3 0.9 0.036
Subject 4 0.5 0.49
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Table 7 Correlation coefficient and p-values as given by a
Pearson comparison test, between the inverse total
number of CD3 T-cell used in spectratype assays and the
spectratye divergence
Subject Correlation coefficient p-value
Subject 1 0.92 0.25
Subject 4 -0.98 0.11
Subject 5 0.66 0.15
Subject 6 0.97 0.03
Subject 7 0.64 0.35
Human subjects
Subjects were enrolled in protocols that were approved by
the Duke University Health System Institutional Review
Board and were reviewed by the Food and Drug Admin-
istration under an Investigational New Drug application.
All subjects were children. The parent(s) of each subject
provided written informed consent.
Table 8 List of TCR BV families and antibodies used in the
flow cytometry assay

















Vβ16 TAMAYA 1.2 TRBV14
Vβ17 E17.5F3 TRBV19
Vβ18 BA62 TRBV18
Vβ20 ELL 1.4 TRBV30
Vβ22 IMMU 546 TRBV2
Vβ23 AF23 TRBV13
The antibodies were purchased from Immunotech (Beckman Coulter) and used
for the analysis. A kit IOTest Beta Mark became available during the study and
was used in place of individually purchased antibodies.
∗Nomenclature of the IMGT, the international ImMunoGeneTics information
system http://www.imgt.org.
Table 9 List of TCR VB families and antibodies excluded
from the flow cytometry studies
Antibody names Clone Family name∗
Vβ13.1 & 13.4 & 13.6 IMMU 222 TRBV6-5 & 6-6 & 6-9
Vβ21.3 IG125 TRBV11-2
These antibodies are included in the kit but were not included in the analysis.
∗Nomenclature of the IMGT, the international ImMunoGeneTics information
system http://imgt.cines.fr.
Flow cytometry
Reference distributions of TCR BV family usage deter-
mined by flow cytometry were generated from peripheral
blood samples of fifty healthy individuals (see Table 10).
Similar distributions of TCR BV usage were derived from
four additional controls and four DiGeorge subjects [19]
who underwent thymus transplantation.
Spectratyping
CD3 T-cells from the peripheral blood of patients were
isolated. RNAwas prepared and used for cDNA synthesis.
Table 10 Mean% of CD4 T-cells that use a TCR BV family as
predicted by the flow cytometry assay























Note that the antibody used in flow cytometry assay covers approximately 70%
of CD4 T-cells.
The values are averaged across 50 normal volunteers.
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The cDNA was used as a template for 23 TCR BV specific
primer pairs to amplify the complete CDR3 region by PCR
[10]. Each PCR product, representing a different TCR BV
family, was size separated by electrophoresis and the prod-
uct lengths were identified using the GeneScan software
(Applied Biosciences). An example of spectratype data in
a healthy adult is presented in Figure 5, which shows the
histograms of the number of CD4 T-cells versus CDR3
length for each TCR BV family.
Kullback-Leibler divergence
Flow Kullback-Leibler divergence
Let P = {Pi, i = 1, ..., nF} be the relative frequencies
corresponding to the ideal, perfectly sampled reference
distribution of BV family i usage, where nF is the num-
ber of BV families (in our case 18). Let p = {pi, i =
1, ..., nF} be the relative frequency of cells that use BV fam-
ily i in individual control/subjects. The null hypothesis is
that a normal polyclonal TCR repertoire has a distribution
identical with that of the reference distribution. Devia-
tion from the normal repertoire seen in subjects can be








The flow Kullback-Leibler divergence is a measure of
the distance between the two frequency distributions or,
Figure 5 CD4 T-cell spectratype data. Spectratype histograms show the number of CD4 T-cells bearing receptors versus CDR3 length for each
TCR BV families tested.
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equivalently, it is the inefficiency of assuming that the dis-
tribution of BV family usage is pi, i = 1, ..., nF , when the
true frequency usage is Pi, i = 1, ..., nF .
Spectratype Kullback-Leibler divergence
Similarly, let p = {pij = qirj/i, i = 1, ..., nF and j =
1, ..., nC}, and P = {Pij = QiRj/i, i = 1, ...nF and j =
1, ...nC}, respectively, be the relative numbers of T-cells
of CDR3 lengths j, given that the BV family i is used
in individual patient/controls and reference controls as
determined by spectratype. Here nC is the number of
CDR3 lengths (in our case 14), (q,Q)i are the rela-
tive frequencies of cells which use the BV family i and
(r,R)j/i the relative frequencies of of cells that have CDR3
length j, given that they use the BV family i. The null
hypothesis is that a normal polyclonal TCR repertoire
has a distribution of CDR3 lengths identical with that
of the reference distribution. Deviation of from the nor-
mal repertoire, as seen in patients, can be quantified by









and the total spectratype divergence, which is the aver-
age of spectratype divergences of TCR BV families i, i ∈






We can combine these two measures to obtain a total






































Sampling bias - theoretical derivation
The distribution of BV family usage (CDR3 length within
a BV family) of a perfectly sampled reference control can
be described by a Lf (Ls)-dimensional multinomial distri-
bution with the parameter vector P, where Pi is the relative
numbers of T-cells that use the BV family (CDR3 length) i.
The distribution of the actual, but not yet observed, BV
family (CDR3 length) usage in individual patient/controls
are subsamples q of the ideal distribution, where qi are the
relative numbers of T-cells that use the BV family (CDR3
length) i. The distance between these two distributions
is given by the parameter d−1, with a large d account-
ing for a closer similarity between P and q. Finally, the
observed distribution of BV family usage (CDR3 length),
p, are samples of n measured events for every individual
patient/control, where pi are the relative numbers of T-
cells that use the BV family (CDR3 length) i. Here Lf (Ls)
is the dimension of the measured space, i.e. the number of
BV families used in the flow cytometry assay, in our case
18 (the number of CDR3 lengths used in spectratyping
assay, in our case 14).
For a large sampling number, n, we can consider the rel-
ative frequencies P, q and p to be continuous variables and
define their probability distribution functions, pdf, as
f (p|P, n, d−1) =
∫
f (p|q, n)f (q|P, d−1)dLiq (10)
where i = f , s. The pdf of p, for npi large enough, can
be approximated using Stirling’s formula (see [9] for a
complete computation). Therefore,























is the Kullback-Leibler divergence between p and q.
As shown in Kepler et al. [9] Laplace’s integration
method with constraints [20] can be used to asymptoti-
cally approximate the integral (10) as follows













log f (p|P, n, d−1) = − nD(p|q) − d−1D(q|P)
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Moreover, as shown in Kepler et al. [9], a Taylor expan-
sion in  = (nd)−1 of qi around pi, leads to the following
expression for (14)































From this, one can derive the expected values, E, of
D(p|P) and sD up to order  to be (for a complete deriva-
tion refer to [9])
E
[










From here we can derive the corrected individual diver-
gence,
Di,corr = Df − Li − 12n , (19)
which relaxes the concern of variability due to sampling
error.
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